Laerdal Acute Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2011
NCT01359878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Asmund S. Laerdal Foundation for Acute Medicine | Laerdal Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

fibrinogen (human) (RiaSTAP) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2